why choose us

First received: November 11, 2024

Clinical Trial: An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Dermatitis Atopic

Study Type: INTERVENTIONAL


Official Title: An Open-label, Drug-drug Interaction Study to Investigate the Effects of Amlitelimab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderate-to-severe Atopic

Brief Summary: This is an open-label, single group, 2-period, Phase 1, single-sequence study.The study duration will be up to 342 days.The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab administration at Week 25).The number of visits will be 23 or 21 visits for participants who decide to continue amlitelimab therapy in the long-term extension study LTS17367 (RIVER-AD) study.

Read more